Novartis Halts Planned Price Increases For Drugs Amid Scrutiny of Relationship With Trump AttorneyAllbiopro2018-07-19T10:56:25+09:007월 19th, 2018|
Genentech, Regeneron Find Spots in Fortune’s Top 100 Employer List for MillennialsAllbiopro2018-07-19T10:55:33+09:007월 19th, 2018|
Revolution Medicines Scores With Up to $500 Million in Oncology Collaboration With SanofiAllbiopro2018-07-19T10:54:42+09:007월 19th, 2018|
Jim Cramer: 3 Biotech Stocks Show Signs They’re Ready to ClimbAllbiopro2018-07-19T10:53:51+09:007월 19th, 2018|
Servier Taps Shire Veteran To Helm New U.S. SubsidiaryAllbiopro2018-07-19T10:53:03+09:007월 19th, 2018|
Pfizer and Eli Lilly’s Osteoarthritis Pain Drug Hits All 3 Endpoints in Phase III TrialAllbiopro2018-07-19T10:52:13+09:007월 19th, 2018|
Rubius Therapeutics Sets IPO Pricing at $23 Per ShareAllbiopro2018-07-19T10:51:23+09:007월 19th, 2018|
Startup Neuraly Launches with $36 Million: Targets Neurodegenerative DiseasesAllbiopro2018-07-19T10:50:33+09:007월 19th, 2018|
New Epilepsy Research at Baylor College of Medicine Provides Insight on Absence SeizuresAllbiopro2018-07-19T10:48:51+09:007월 19th, 2018|
Johns Hopkins startup Neuraly plans phase 1 Parkinson’s trial with $36M roundAllbiopro2018-07-19T10:48:01+09:007월 19th, 2018|
Roche’s Tecentriq extends its hot streak with liver cancer combo breakthroughAllbiopro2018-07-19T10:47:09+09:007월 19th, 2018|
Under scrutiny for Cohen deal, Novartis calls off further price hikes in 2018Allbiopro2018-07-19T10:46:18+09:007월 19th, 2018|
Novartis runs into Kymriah production glitch in new DLBCL indicationAllbiopro2018-07-19T10:45:27+09:007월 19th, 2018|
Sonnet Selects Oncobiologics to Take I-O Assets into the ClinicAllbiopro2018-07-19T10:43:45+09:007월 19th, 2018|
CEO Weber sees China as Takeda’s second-largest business—in the long run: reportAllbiopro2018-07-19T10:43:21+09:007월 19th, 2018|
Eisai obesity drug Belviq may have an edge with new heart-safety data—but to what end?Allbiopro2018-07-19T10:42:56+09:007월 19th, 2018|
